SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
June 9, 1998
----------------
(Date of Report)
ENTROPIN, INC.
------------------------------------------------------
(Exact Name of Registrant as specified in its charter)
Colorado 33-23693 84-1090424
- ---------------------------- ------------ -------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
45926 Oasis Street, Indio, CA 92201
-----------------------------------------------------------
(Address of principal executive offices including zip code)
(760) 775-8333
---------------------------------------------------
(Registrant's telephone number including area code)
N/A
-------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
ITEM 5. OTHER EVENTS.
- ----------------------
On June 3, 1998, the Registrant issued the following press release
relating to the formation of its Science and Medical Advisory Board:
NEWS RELEASE
FOR IMMEDIATE RELEASE
ENTROPIN, INC. ANNOUNCES THE FORMATION OF SCIENCE AND MEDICAL ADVISORY BOARD
Indio, CA, June 3, 1998 - Entropin Inc. (OTC Bulletin Board: ETOP) today
announced the formation of the Company's Science and Medical Advisory Board.
This group of eminent members of the medical and research communities will
assist Entropin in various aspects of the clinical and regulatory processes for
completing the Phase III Clinical Trial and the filing of a successful New Drug
Application with the FDA for its first product, Esterom(R). Esterom(R) is a
topically-applied, patented medicinal preparation for the treatment of impaired
range of motion associated with acute lower back sprain and acute painful
shoulder.
The five member board and their brief biographies include:
Arthur Hull Hayes, Jr., M.D., currently Vice Chairman and Medical Director,
Nelson Communications, Inc. and the President of MediScience Associates, Inc.
the regulatory/medical consulting division of Nelson Communications. Dr. Hayes
was awarded an NIH fellowship in neuropharmacology research at Cornell
University Medical College in 1960. He joined Cornell's faculty serving as
Associate Professor of Medicine and Pharmacology, Associate Dean for Academic
Affairs, and Attending Physician, The New York Hospital. He established and
directed the hospital's first cardiac pacemaker clinic. In 1972, Dr. Hayes
became Professor of Medicine and Pharmacology, founding Director of the Division
of Clinical Pharmacology, and Attending Physician at the Pennsylvania State
University College of Medicine, Hershey Medical Center where he also served as
chairman of the admissions committee and established a referral-research
hypertension clinic. He also chaired the hospital Pharmacy and Therapeutics
Committee and served on the institutional review board. In April, 1981 Dr. Hayes
was appointed Commissioner of Food and Drugs (FDA) and an Assistant Surgeon
General, positions he held until September, 1983 when he was named Provost and
Dean, Professor of Medicine, Pharmacology and Family & Community Medicine
(Public Health), and Director of the Institute of Human Values in Medical Ethics
at the New York Medical College. Dr Hayes is the past president and chief
executive officer and member of the board of directors of EM Pharmaceuticals,
Inc., a North American subsidiary of E. Merck, Darmstadt, Germany. He has
received numerous scientific and public service awards and honors, is a Charter
Diplomate of the American Colleges of Physicians, Cardiology, and Chest
Physicians, the American Academy of Pharmaceutical Physicians, the New York
Academy of Medicine and the Royal College of Medicine. He serves on a number of
academic, commercial and foundation boards of directors, advisory committees and
editorial boards, and is the chairman of the Council on Family Health. He has
published over 100 scientific and public policy articles and book chapters,
delivered more than 2500 professional lectures and testified at 24 Congressional
Hearings.
- 2 -
<PAGE>
Gerhard Levy, Pharm.D., is University Distinguished Professor of
Pharmaceutics Emeritus (active) at the State University of New York at Buffalo
School of Pharmacy, where he has served since 1958. Dr. Levy's research
interests are in the areas of pharmacokinetics, kinetics of drug action and
biopharmaceutics. He has been a member of the editorial board or editorial
advisory board of 15 journals, including International Journal of Clinical
Pharmacology, Clinical Pharmacology and Therapeutics, Pharmacy Today,
Perspectives in Biochemical Pharmacology and Clinical Pharmacokinetics. He has
authored over 550 publications and is included in the list of Most Cited
Scientists in the November 1990 issue of the Scientist. He has served on a
number of committees of the Food and Drug Administration and was a principal
consultant to Bureau of Drugs Advisory Panel System. He has consulted for the
World Health Organization and was appointed to a distinguished visiting
professor position at several universities, including Hebrew University in
Israel, University of Iowa, University of Leiden in the Netherlands and the
University of Manchester in Great Britain. Among many elected memberships and
numerous awards for achievement and excellence, Dr. Levy is the recipient of the
first Lifetime Achievement in the Pharmaceutical Sciences Award of the
International Pharmaceutical Federation.
Kenneth Lloyd Melmon, M.D., is currently Professor of Medicine and
Pharmacology and Associate Dean for Postgraduate Medical Education at the
Stanford University School of Medicine. He is past president of the American
Federation of Clinical Research, the Western Society of Clinical Investigation,
the American Society of Clinical Investigation and the Western Association of
Advancement of Science and the Council of the International Society of
Immunopharmacology. He was a recipient of a Burroughs Wellcome Clinical
Pharmacology Scholar award, a National Institutes of Health Special Fellowship
award and a John Simon Guggenheim Memorial Foundation Fellowship for
Experimental Studies in Clinical Biochemistry and Immunopharmacology. Dr. Melmon
has authored over 300 original papers and book chapters, has served on the
editorial board of a dozen scientific journals, including New England Journal of
Medicine, American Journal of Physiology, Journal of Clinical Investigation and
the Annals of Internal Medicine, and has provided editorial consultation for
numerous others. In recent years, he has been a member of the National Research
Council of the Institute of Medicine, the Committee on Technological Innovation
in Medicine of the National Academy of Sciences and the National Board of
Medical Examiners. He served as the chairperson of the Commission of
Prescription Drug Use from 1976 to 1980. In 1978, he joined the Stanford
University School of Medicine as Chairman of the Department of Medicine where he
initiated programs of academic-industry interface that have made possible
numerous technology transfers between basic and clinical science. In 1994 he was
honored with the Oscar B. Hunter Award of the American Society of Clinical
Pharmacology and Therapeutics.
Lester A. Mitscher, Ph.D. is currently University Distinguished Professor,
Department of Medicinal Chemistry at the University of Kansas. He is past
chairman of the Medicinal Chemistry Division of the American Chemical Society
and chairman of the American Society for Pharmacognosy. He is a fellow of the
American Association for Advancement of Science and is the recipient of the
Research Achievement Award in Natural Products Chemistry of the American
Pharmaceutical Association Academy of Pharmaceutical Sciences, the Volweiler
Award for Research Achievement of the American Association of Colleges of
Pharmacy, the Smissman Award in Medicinal Chemistry of the American Chemical
Society and the Higuchi-Simons Award in the Biomedical Sciences. Dr. Mitscher
has consulted with numerous pharmaceutical companies, including Proctor and
Gamble, Panax Laboratories, Abbott Laboratories, G.D. Searle, Sandoz
Laboratories, and DuPont Merck Labs. He has served as chairman of the Biological
- 3 -
<PAGE>
and Natural Products Section of the National Institutes of Health, chairman of
the Hematology and Chemotherapy Study Section of the American Cancer Society and
chairman of the Cooperative Drug Screening Program of the International
Organization for Chemistry in Development, World Health Organization. Dr.
Mitscher has authored several books, over 200 original papers and book chapters,
and served as an editor of nearly a dozen professional journals, including The
Journal of Antibiotics, Allergy and Infectious Diseases, Medicinal Research
Reviews (editor-in-chief) and the Journal of Medicinal Chemistry.
William Charles McMaster, M.D. is currently Professor and Chief Department
of Orthopaedic Surgery at the University of California, Irvine. He also has a
private practice in Orange County, California. He is a member of the American
Orthopaedic Society for Sports Medicine, has held numerous elected offices in
the California Orthopaedic Association, the American Academy of Orthopaedic
Surgery and the Western Orthopaedic Association, is a fellow of the American
College of Surgeons and a founding member of the Society for Biomaterials and
Association for Arthritic Hip and Knee Surgery. He served as team physician for
the 1980 United States Olympic and national swimming team at the Hawaii
International Invitational, 1981 USA/USSR swimming competition in Kiev, the 1984
United States Olympic swimming team, Fifth World Swimming Championships in
Madrid, Spain and Sixth World Swimming Championships in Perth, Australia. In
1988, he served as Physician Specialist for the XXIII Olympiad in Los Angeles,
California. Dr. McMaster has authored over 100 publications and presentations,
in his area of research specialty, sports medicine and orthopaedic surgery.
Commenting on the Science and Medical Advisory Board, Entropin's Chairman Dr.
Higgins D. Bailey said "We are extremely pleased with our Advisory Board. The
experience and insight each member brings to the Company in its efforts to
commercialize its first product, Esterom(R), is invaluable. We also are pleased
by the confidence that they show in Esterom(R) in joining us and look forward to
their participation."
Entropin, Inc. is a pharmaceutical research company that is completing
development of the Phase III Clinical Trial and proceeding towards its New Drug
Application with the FDA for its first product, Esterom(R). Esterom(R) is a
topically applied compound for the treatment of impaired range of motion
associated with acute lower back sprain and acute painful shoulder. Seven
patents have been granted by the U.S. Patent Office in connection with this
medication.
This announcement contains various "forward-looking statements" within the
meaning of federal securities laws. Investors and potential investors should
recognize that such statements express expectations which may or may not occur.,
Whether such expectations occur is subject to uncertainty caused, among other
things, by factors that are beyond the control of Entropin's management or other
unforeseeable influences unknown at this time. Investors are urged to be
cautious in assessing the impact of such "forward-looking statements."
For further information contact Higgins Bailey at (760) 775-8333, or Michael
Underwood at (303) 534-1119.
- 4 -
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date: June 9, 1998 ENTROPIN, INC.
By /s/ Wellington A. Ewen
----------------------------------
Wellington A. Ewen
Chief Financial Officer
- 5 -
